Article
Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
BMC cancer - 22 May 2017
Darwanto Agus, Hein Anne-Mette, Strauss Sascha, Kong Yi, Sheridan Andrew, Richards Dan, Lader Eric, Ngowe Monika, Pelletier Timothy, Adams Danielle, Ricker Austin, Patel Nishit, Kühne Andreas, Hughes Simon, Shiffman Dan, Zimmermann Dirk, Te Kaat Kai, Rothmann Thomas
Abstract excerpt
BACKGROUND: The detection of somatic mutations in primary tumors is critical for the understanding of cancer evolution and targeting therapy. Multiple technologies have been developed to enable the detection of such mutations. Next generation sequencing (NGS) is a new platform that is gradually becoming the technology of choice for genotyping cancer samples, owing to its ability to simultaneously interrogate many...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.